Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates

Journal of Clinical Pharmacology
Melanie WilbauxMarc Pfister

Abstract

Sepsis remains a major cause of mortality and morbidity in neonates, and, as a consequence, antibiotics are the most frequently prescribed drugs in this vulnerable patient population. Growth and dynamic maturation processes during the first weeks of life result in large inter- and intrasubject variability in the pharmacokinetics (PK) and pharmacodynamics (PD) of antibiotics. In this review we (1) summarize the available population PK data and models for primarily renally eliminated antibiotics, (2) discuss quantitative approaches to account for effects of growth and maturation processes on drug exposure and response, (3) evaluate current dose recommendations, and (4) identify opportunities to further optimize and personalize dosing strategies of these antibiotics in preterm and term neonates. Although population PK models have been developed for several of these drugs, exposure-response relationships of primarily renally eliminated antibiotics in these fragile infants are not well understood, monitoring strategies remain inconsistent, and consensus on optimal, personalized dosing of these drugs in these patients is absent. Tailored PK/PD studies and models are useful to better understand relationships between drug exposures and...Continue Reading

References

Jan 1, 1976·The American Journal of the Medical Sciences·M G BergeronL Weinstein
Jul 1, 1978·Antimicrobial Agents and Chemotherapy·G HumbertG Oksenhendler
Jun 1, 1976·Antimicrobial Agents and Chemotherapy·C Q EdwardsP S Lietman
Nov 1, 1992·Clinical Pharmacokinetics·M A de CosJ A Armijo
Jul 1, 1992·Antimicrobial Agents and Chemotherapy·B A ChristenssonS R Norrby
May 1, 1992·The Pediatric Infectious Disease Journal·N KacetP Lequien
Jul 1, 1991·Clinical Pharmacology and Therapeutics·K FattingerF Follath
Nov 1, 1991·Mayo Clinic Proceedings·R S Edson, C L Terrell
Oct 1, 1990·Clinical Pharmacokinetics·C M Paap, M C Nahata
Jan 1, 1988·Developmental Pharmacology and Therapeutics·A H ThomsonB Whiting
May 1, 1988·Clinical Pharmacology and Therapeutics·T A GolperW M Bennett
Jun 7, 1985·The American Journal of Medicine·G L Drusano, H C Standiford
Nov 1, 1984·British Journal of Clinical Pharmacology·A W KelmanL A Samba-Donga
Nov 1, 1984·Antimicrobial Agents and Chemotherapy·S R NorrbyJ Y Hsieh
Feb 1, 1982·Archives of Disease in Childhood·H Feldman, J P Guignard
Dec 1, 1994·Antimicrobial Agents and Chemotherapy·M D ReedJ L Blumer
Jan 1, 1995·The Pediatric Infectious Disease Journal·H Skopnik, G Heimann
Jan 1, 1995·The Pediatric Infectious Disease Journal·P R Harris, R Figueroa-Colon
Aug 1, 1994·Clinical Pharmacology and Therapeutics·R E SeayB E Edgren
Jan 1, 1993·The Journal of Antimicrobial Chemotherapy·F Sörgel, M Kinzig
Aug 1, 1996·The Pediatric Infectious Disease Journal·J L Blumer
Jun 1, 1997·The Journal of Antimicrobial Chemotherapy·C D FreemanC H Nightingale
Nov 14, 1997·Clinical Pharmacology and Therapeutics·M de HoogJ N van den Anker
Dec 31, 1997·Journal of Pharmaceutical Sciences·B G CharlesN Debuse
Mar 27, 1998·European Journal of Clinical Pharmacology·J H BothaM Adhikari
Dec 16, 1998·Therapeutic Drug Monitoring·M YasuharaR Hori
Apr 2, 1999·Pediatrics·J P Guignard, A Drukker
Oct 19, 1999·Archives of Disease in Childhood. Fetal and Neonatal Edition·C Grimsley, A H Thomson
May 9, 2000·Clinical Pharmacology and Therapeutics·M de HoogJ N van den Anker
Jun 29, 2000·Clinical Pharmacology and Therapeutics·J M TréluyerG Pons
Nov 30, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·F GalliniG Tortorolo
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·M TodY Aujard
May 22, 2001·Therapeutic Drug Monitoring·A C FalcãoM Pardo
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·J M Andrews
Sep 11, 2001·Journal of Clinical Pharmacology·E V CapparelliJ D Connor
Nov 9, 2001·European Journal of Clinical Pharmacology·N BleyzacG Aulagner
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·J M TréluyerG Pons
May 16, 2002·Clinical Pharmacology and Therapeutics·Matthijs de HoogJohn N van den Anker

❮ Previous
Next ❯

Citations

May 5, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Raffaele CoppiniKarel Allegaert
Jun 9, 2016·Expert Review of Clinical Pharmacology·Janneke M BrusseeCatherijne A J Knibbe
Sep 10, 2016·British Journal of Clinical Pharmacology·Serge CremersBrian Shine
Sep 15, 2016·Expert Opinion on Drug Metabolism & Toxicology·Anne SmitsKarel Allegaert
Jan 10, 2017·Expert Review of Clinical Pharmacology·Aggeliki KontouEmmanuel Roilides
Feb 22, 2018·Antimicrobial Agents and Chemotherapy·Helgi PadariIrja Lutsar
May 24, 2018·Paediatrics and International Child Health·Aline FuchsJohannes N Van Den Anker
Sep 25, 2018·Journal of Clinical Pharmacology·John van den AnkerGregory L Kearns
Jul 18, 2019·Therapeutic Innovation & Regulatory Science·Kathleen M JobRobert M Ward
Jan 16, 2020·Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo·Amanda Roseane Farias do NascimentoRand Randall Martins
Oct 1, 2020·Journal of Clinical Pharmacology·Yue-E WuWei Zhao
Nov 14, 2018·Frontiers in Pediatrics·Tamara van DongeMarc Pfister
Feb 12, 2019·Expert Review of Clinical Pharmacology·Karel AllegaertJohn Van Den Anker
Jun 27, 2019·The Journal of Antimicrobial Chemotherapy·Fleur M KeijGerdien A Tramper-Stranders
Feb 6, 2017·Journal of Clinical Pharmacology·Gilbert KochMarc Pfister
Mar 20, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Jeremiah D MomperSanjay K Nigam
Feb 20, 2019·Healthcare·John van den Anker, Karel Allegaert
Jul 10, 2019·Journal of Clinical Pharmacology·Hechuan WangVijay Ivaturi
Apr 28, 2019·BMC Pediatrics·Ramon Duarte LeopoldinoAntónio Gouveia Oliveira
Sep 11, 2019·Journal of Clinical Pharmacology·Tamara van DongeMarc Pfister
Jan 31, 2019·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Edit Muhari-Stark, Gilbert J Burckart
Sep 11, 2019·Journal of Clinical Pharmacology·Yifei ZhangJian Wang
Dec 29, 2020·International Journal of Antimicrobial Agents·Hubert C ChuaBrian T Tsuji
Dec 16, 2020·Antimicrobial Agents and Chemotherapy·Hiroshi SasanoKazuhiko Hanada
Apr 23, 2021·Drug Design, Development and Therapy·Xiaohui HuangJihui Chen
Jun 30, 2021·Journal of Clinical Pharmacology·John van den Anker, Karel Allegaert
Jun 30, 2021·Journal of Clinical Pharmacology·Jian WangGilbert J Burckart
Jul 28, 2021·Expert Review of Clinical Pharmacology·Quyen TuJason A Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.